Blog
RSS FeedPosted by Michael Wonder on 11 Jun 2026
Eli Lilly Canada welcome Quebec public reimbursement of Verzenio (abemaciclib) for mBC following successful PCPA negotiation
10 June 2026 - Eli Lilly Canada is pleased to announce that Verzenio (abemaciclib) is now publicly reimbursed in Québec ...
Posted by Michael Wonder on 05 Jun 2026
First new NHS treatment in over 20 years recommended for women with resistant ovarian cancer
4 June 2026 - The treatment uses a targeted therapy that seeks out a specific protein found on the surface of ...
Posted by Michael Wonder on 01 Jun 2026
Expanded listing to save leukaemia patients $35.5 million a year
1 June 2026 - Eligible patients with leukaemia will have access to $25 scripts for two new treatments following their ...
Posted by Michael Wonder on 29 May 2026
BeOne Medicines receives positive reimbursement recommendations from CDA-AMC and INESSS for Tevimbra in first-line nasopharyngeal carcinoma
28 May 2026 - BeOne Medicines today announced that Canada's Drug Agency and the Institut national d'excellence en santé et ...
Posted by Michael Wonder on 27 May 2026
Pfizer's Braftovi becomes first Pfizer therapy to receive priority access under Ontario's FAST program, accelerating treatment for Canadians with metastatic colorectal cancer
26 May 2026 - Pfizer Canada announces that Braftovi (encorafenib) will be funded under Ontario's Funding Accelerated for Specific Treatments ...
Posted by Michael Wonder on 15 May 2026
Over 1,500 people set to benefit from first immunotherapy for aggressive stomach cancer
14 May 2026 - Over 1,500 people set to benefit from first immunotherapy for aggressive stomach cancer. ...
Posted by Michael Wonder on 03 May 2026
Affordable treatment for Australians with colorectal cancer
3 May 2026 - Australians with stage 4 colorectal cancer are among those who will benefit from new drug listings ...
Posted by Michael Wonder on 22 Apr 2026
New life-extending treatment given the green light for people with rare form of bile duct cancer
21 April 2026 - A new targeted treatment for a rare and aggressive form of bile duct cancer has been recommended ...
Posted by Michael Wonder on 19 Apr 2026
New take at home drug recommended for people with chronic lymphocytic leukaemia
17 April 2026 - NICE has recommended a new take at home tablet for some people with chronic lymphocytic leukaemia whose ...
Posted by Michael Wonder on 16 Apr 2026
The Australian Government is continuing to deliver cheaper medicines with Australians living with lung or bladder cancer to pay less for new and expanded PBS medicines
16 April 2026 - The Australian Government is continuing to deliver cheaper medicines with Australians living with lung or bladder ...
Posted by Michael Wonder on 14 Apr 2026
Cancer patient’s plea for Pfizer to rejoin PBS talks on breakthrough drug
14 April 2026 - Pharmaceutical giant Pfizer has abandoned negotiations to have a breakthrough cancer drug listed on the Pharmaceutical ...
Posted by Michael Wonder on 09 Apr 2026
PHARMAC to fund two new combination treatments, and widen access to another, for people with a type of blood cancer
9 April 2026 - From 1 May 2026, people living with chronic lymphocytic leukaemia will be able to access two ...
Posted by Michael Wonder on 08 Apr 2026
Cancer clinicians call for three actions Canada's health systems should take to improve cancer care
7 April 2026 - April Cancer Awareness Month a good time for concrete action ...
Posted by Michael Wonder on 07 Apr 2026
PHARMAC widens access to two melanoma medicines
7 April 2026 - PHARMAC will widen access to two melanoma medicines, giving New Zealanders another funded immunotherapy option and ...
Posted by Michael Wonder on 29 Mar 2026
Expanded immunotherapy PBS listing to treat more cancers
29 March 2026 - The Albanese Government is continuing to deliver cheaper medicines with thousands more Australians living with advanced ...